Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Resonance Health's share price for the quarter that ended in Dec. 2023 was A$0.06. Resonance Health's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 466.89 Mil. Therefore, Resonance Health's market cap for the quarter that ended in Dec. 2023 was A$28.01 Mil.
Resonance Health's quarterly market cap
declined
from Dec. 2022 (A$27.67 Mil) to Jun. 2023 (A$19.37 Mil) but then
increased
from Jun. 2023 (A$19.37 Mil) to Dec. 2023 (A$28.01 Mil).
Resonance Health's annual market cap
declined
from Jun. 2021 (A$71.48 Mil) to Jun. 2022 (A$25.82 Mil) and
declined
from Jun. 2022 (A$25.82 Mil) to Jun. 2023 (A$19.37 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Resonance Health's Enterprise Value for Today is A$28.83 Mil.
Resonance Health Market Cap Historical Data
The historical data trend for Resonance Health's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Resonance Health's Market Cap
For the Health Information Services subindustry, Resonance Health's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health's Market Cap Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Market Cap distribution charts can be found below:
* The bar in red indicates where Resonance Health's Market Cap falls into.
Resonance Health Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Resonance Health's Market Cap for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Resonance Health Market Cap Related Terms
Thank you for viewing the detailed overview of Resonance Health's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, and HepaFat-Scan. The company's operating segment includes Services; Research and Development and Corporate. It generates maximum revenue from the Services segment. Geographically, it derives a majority of its revenue from North America and Europe-Middle-East-Africa (EMEA) and also has a presence in Asia/Pacific.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:RHT has been successfully added to your 